Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines After FDA Approval – Reuters Health

Read article - Features research led by Steven Woloshin, professor of medicine, community and family medicine, and of the Dartmouth Institute for Health Policy and Clinical Practice, that found that drug companies aren't meeting the Food and Drug Administration's requirement to study possible side effects and alternative doses for medicines once they hit the broader market. Woloshin and his colleagues looked at federal records and found that among the 614 studies mandated in 2009 and 2010, 20 percent were never started and 9 percent have been delayed.